ThymalinТималин
What is it?
A thymus-derived peptide preparation studied in immune-system research. Unlike a single synthetic peptide, it contains a mixture of tissue-derived components.
Identity / background source ↗
Research context
A 1983 thermal-injury paper investigated Thymalin as an adjunct to comprehensive burn care. Its findings concern that clinical setting and do not establish a general recovery benefit.
- Working classification
- Peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Chita Medical Institute
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Clinical comparison
- Study methods
- —Adjunctive burn care
- Independent replication
- —Not assessed
- Source access
- —Russian full text
- Safety evidence
- —Not assessed
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Linked sources
Explore the research map and unresolved leads ↗
The use of thymalin for the treatment of thermal injury
B. I. Kuznik, V. Kh. Khavinson, V. G. Morozov, G. B. Budazhabon, V. A. Sizonenko, V. N. Kuzmin · Kazan Medical Journal. 64(1):39–42
The paper reports immune and hemostatic changes during adjunctive burn treatment. The authors explicitly acknowledge that comprehensive therapy contributed to the observed changes.
- Population / setting
- Patients receiving comprehensive treatment for thermal injury
- What was checked
- Publisher page, Russian text, and English abstract checked. Full risk-of-bias review pending.
Limitations & review scope
- Adjunctive treatment complicates causal attribution.
- Randomization and blinding have not been verified.
- Disease-specific observations do not establish benefits in healthy users.
Source checked 2026-09-27. This is a source-linked record, not a completed evidence review.